(Q42375592)

English

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study

scientific article published on 9 October 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study (English)

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Hans-Peter Hartung

6

object named as

Hans-Peter Hartung

1 reference

Europe PubMed Central

28 October 2017

PMC publication ID

3

object named as

Giancarlo Comi

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

author name string

Mark S Freedman

1

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Thomas P Leist

2

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Bruce Ac Cree

4

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Patricia K Coyle

5

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Patrick Vermersch

7

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Doris Damian

8

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Fernando Dangond

9

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

publication date

9 October 2017

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Multiple sclerosis journal - experimental, translational and clinical

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

3

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

4

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

2055217317732802

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Both cladribine and alemtuzumab may effect MS via B-cell depletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Assessing response to interferon-β in a multicenter dataset of patients with MS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Optimizing therapy early in multiple sclerosis: An evidence-based view

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Treatment optimization in MS: Canadian MS Working Group updated recommendations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Development of oral cladribine for the treatment of multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

28 May 2018

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

16 August 2018

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

16 August 2018

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

16 August 2018

Scoring treatment response in patients with relapsing multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

16 August 2018

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637982

16 August 2018

Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/29051829

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1177/2055217317732802

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

28 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42375592&oldid=1570027059"